Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=80 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Scleroderma · Raynaud's Syndrome
Primary: Change in Digital Blood Flow From Pre- to Post-injection. — -36.19; -6.10 Blood flow, measured in LDI flux units,
N/A N=28 Predictive of Biomarkers of Healing in Chronic Venous Ulceration of the Lower Limb
Varicose Ulcer
Primary: Identification of Biomarkers Predictive of Ulcer Healing. — 9 Number of biomarkers
Phase 2 N=12 A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
Necrobiosis Lipoidica
Primary: Evaluation of Patients With Adverse Events — 10 Participants
N/A N=21 Evaluation of Heel Offloading Devices for Reducing Heel Contact Pressures in Healthy Volunteers
Heel Pressure Ulceration Prevention Strategies
Primary: Average Contact Force Exerted on the Heel — 60.25; 39.74; 5.57; 29.34 mmHg — p=<0.00005
Phase 3 N=56 Early Short-term Antibiotic Therapy in Penetrating Abdominal Trauma, 3 vs 7 Days
SURGICAL SITE INFECTION
Primary: Surgical Site Infection — 6; 3 participants — p=<0.05
Phase 4 N=189 Study Of Celecoxib In Healthy Subjects
Healthy Volunteers
Primary: Incidence of Gastroduodenal Ulcers — 1.4; 27.6; 2.7 Percent — p=<0.0001
Phase 2 N=121 Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
NSAID-induced Gastroduodenal Injury · Ulcers · Rheumatoid Arthritis
Primary: Number of Participants With Gastric Ulcers — 7; 5; 7; 4 Participants
Phase 3 N=434 Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Gastric Ulcer
Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 9; 50 Participants — p=0.001
Phase 2 N=204 Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
Upper Gastrointestinal Mucosal Damage
Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants
Phase 3 N=420 Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Gastric Ulcer
Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 15; 51 Participants — p=0.001
N/A N=158 Clinical Improvement and in Quality of Life-Functional Dyspepsia-
Psychogenic Dyspepsia
Primary: Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS) — 73.72; 65.31; 71.85; 64.89 units on a scale
Phase 2 N=247 Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
Phase 4 N=21 The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries
Pelvic Ring Fractures
Primary: Visual Analogue Scale — 6.0; 6.8; 5.5; 3.7 units on a scale
Phase 4 N=29 A Multi-centre Evaluation of the Performance of Window Dressings on Subjects With High Risk Pressure Ulceration
Pressure Ulcer
Primary: Erythema ( No/Yes) — 5; 24; 16; 13 participants